As we move forward with diabetes technology development in 2023, there’s a feeling of both familiarity and anticipation as many innovations which had been expected for 2021 were unfortunately delayed due to the ongoing global pandemic. Despite this delay, it is an inspiring moment for those living with Diabetes looking ahead to new products such as insulin pens and pumps along with continuous glucose monitors (CGMs) that are anticipated to revolutionize daily management strategies – including Smart Closed Loop Tech also referred to Artificial Pancreas or Automated Insulin Delivery systems.
Chris Stocker with Diabetes 365 is going to share with us some of the advancements in the Health and Diabetes technology world. The world of Diabetes is an ever changing one, and there are lots of great developments coming to the Diabetes community
Tandem Diabetes Care
Technology is revolutionizing diabetes care, giving people with the condition unprecedented control over their own medical devices. For the first time, we are on the brink of having smartphone apps that allow us to remotely dose insulin – a game-changer for PWDs! With approval from Food and Drug Administration (FDA) imminent, this breakthrough promises revolutionary improvements in quality of life.
Phone-Based Mobile Blousing
Tandem Diabetes Care is blazing a trail in diabetes technology, with the launch of its new t: connect app. Offering unparalleled convenience and control to its users, this smartphone application allows for remote bolusing – or insulin dosing management – via mobile device. This exciting advancement could revolutionize how diabetics manage their conditions on the go!
After much anticipation, the FDA recently approved Tandem’s expanded mobile app functionality. While this marks an important advancement in their technology journey, it also prepares for a revolutionary transition – introducing a new insulin pump form factor in 2012!
Tandem Mobi (Formerly T: Sport)
Tandem Mobi, formerly the prototype “t: sport”, made its public debut at TAdem’s R&D Day in December 2021. This revolutionary mini-pump features smartphone control and is designed to make diabetes management easier than ever before!
Tandem Diabetes Care Inc. has just released the t: slim X2 OmniPod, a revolutionary hybrid mini-pump with both an infusion set connector and adhesive for wearing on the body. This groundbreaking device is only 4 inches in size yet can hold 200 units of insulin in its cartridge. Versatile features including wireless charging capability, bolus button operation through iOS or Android smartphone apps, waterproof design, and compatibility with the latest iCGM devices like Dexcom G6 make it truly a one-of-a-kind product! Plus, users benefit from Tandem’s innovative Automated Insulin Delivery algorithm that delivers seamless integration of Control IQ functions as well as upcoming four-inch infusion sets currently under development.
Tandem is hopeful of receiving FDA approval on the mobile bolusing feature soon. Then, it plans to introduce its Tandem Mobi plan by 2023, with a potential launch as early as 2022 if all goes according to schedule.
Studies have shown that those who use a form of a CGM tend to have a little better control of their Diabetes. Insurance companies have taken notice of this. Certain individuals may qualify for low premiums on life insurance with type 1 diabetes who utilize technology for their Diabetes conditions.
Medtronic Diabetes Technology
Minimed 780 With CGM Sensor 4 From Medtronic Diabetes Technology
Medtronic’s latest advancement in diabetes tech is the 780G Advanced Hybrid Closed Loop system. Building on their previous 670G and 770G models, this new insulin pump/CGM sensor combo offers Bluetooth for remote technology updating plus a sleek vertical design that has been said to look more modern compared to past iterations resembling 80s pagers. This cutting-edge tech promises users convenient maintenance of blood sugar levels with an enhanced form factor reflective of today’s modern aesthetic needs.
The 780G system from Medtronic is here with many innovative features! The Guardian 4 CGM sensor requires minimal calibration and no fingerstick tests for up to 7 days of wear. Plus, For those seeking an optimal blood glucose range, the automatic correction bolus delivery ensures users receive corrections every 5 minutes – even if they miss their meal dose.
Medtronic’s new diabetes management system is a revolutionary development in the market, with adjustable glucose targets and insulin action duration times that surpass all other commercial closed-loop systems. It also offers Bluetooth capabilities for data sharing and remote monitoring as well as convenient software updates – something not currently available on any existing device aside from Tandem t: slim X2. Most impressively of all, this groundbreaking technology has been designed to be accessible even to children aged 2 or above!
Following their investor update at the close of 2020, Medtronic had planned to soon file for review a 780G. However, this process was postponed until Feb 23 2021 due to an FDA warning about key aspects of its facilities and product development. As such, the timeline for approval and launch is currently uncertain.
Eversense Implanted For 180 Days
The revolutionary Eversense CGM, developed by Senseonics and distributed by Ascensia Diabetes Care, has been available in the U.S. since 2018 to monitor blood glucose levels without fingersticks or injections. With a current three-month wear duration, there is an even better version under development that could be worn for 180 days with only one calibration per day required – pending FDA approval of course! An answer from regulators may come as soon as late 2023 so keep your eyes peeled for this exciting innovation down the line!
While many people with Diabetes live with Neuropathy or other complications, technology is helping those with a chronic illness live a better life. Nothing is easy with Diabetes, but advancements in technology are a welcomed site.
